Age of onset of mental disorders: A review of recent literature

Current Opinion in Psychiatry

Volumn 20, Issue 4, 2007, Pages 359-364

  Kessler, Ronald C ^a   Amminger, G Paul ^b   Aguilar Gaxiola, Sergio ^c   Alonso, Jordi ^d   Lee, Sing ^e   Üstün, T Bedirhan ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Age of onset; Early intervention; Mental disorders; Prevention; WHO world mental health survey initiative

Indexed keywords

ADOLESCENCE; ADULTHOOD; AGE DISTRIBUTION; ANXIETY DISORDER; CHILDHOOD; DISEASE SEVERITY; EARLY INTERVENTION; EPIDEMIOLOGICAL DATA; HEALTH SURVEY; HUMAN; IMPULSE CONTROL DISORDER; LIFESPAN; MENTAL DISEASE; MENTAL HEALTH; MOOD DISORDER; ONSET AGE; PHOBIA; PREVALENCE; PSYCHIATRIC TREATMENT; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANXIETY DISORDERS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; PHOBIC DISORDERS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 34249980658     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32816ebc8c     Document Type: Review

References (50)

1. Amminger GP, Harris MG, Conus P, et al. Treated incidence of first-episode psychosis in the catchment area of EPPIC between 1997 and 2000. Acta Psychiatr Scand 2006; 114:337-345.
2. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46:871-881.
3. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001; 31:381-400.
4. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64:19-28. The limitations of screening for psychosis in population surveys were highlighted by comparing clinician-based assessments of psychosis based on CIDI screens with data from a population registry and documenting substantial underrepresentation in the survey.
5. Jenab M, Riboli E, Ferrari P, et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer 2006; 95:406-415.
6. Yan LL, Liu K, Daviglus ML, et al. Education, 15-year risk factor progression, and coronary artery calcium in young adulthood and early middle age: the Coronary Artery Risk Development in Young Adults study. JAMA 2006; 295:1793-1800.
7. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994; 344:1398-1402.
8. Lauronen E, Miettunen J, Veijola J, et al. Outcome and its predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Eur Psychiatry 2007; 22:129-136.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
10. Halli SS, Rao KV, Halli SS. Advanced Techniques of Population Analysis. NY: Plenum; 1992.
11. Amminger GP, Leicester S, Yung AR, et al. Early-onset of symptoms predicts conversion to nonaffective psychosis in ultra-high risk individuals. Schizophr Res 2006; 84:67-76. The paper examined AOO of psychiatric symptoms as predictors of conversion to nonaffective and affective psychosis in help-seeking individuals at ultra-high risk for schizophrenia. Early-onset of psychiatric symptoms were found to be specifically associated with conversion to nonaffective psychosis but not affective psychosis. This finding suggests that early AOO of certain psychiatric symptoms is an independent factor relevant for defining samples specifically at risk for schizophrenia.
12. Klosterkotter J, Ruhrmann S, Schultze-Lutter F, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 2005; 4:161-167.
13. Kendall PC, Kessler RC. The impact of childhood psychopathology interventions on subsequent substance abuse: policy implications, comments, and recommendations. J Consult Clin Psychol 2002; 70:1303-1306.
14. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24:19-39.
15. Clark DB, Jones BL, Wood DS, Cornelius JR. Substance use disorder trajectory classes: diachronic integration of onset age, severity, and course. Addict Behav 2006; 31:995-1009.
16. Nierenberg AA, Quitkin FM, Kremer C, et al. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 2004; 29:1012-1018.
17. Kessler RC, Haro JM, Heeringa SG, et al. The World Health Organization World Mental Health Survey Initiative. Epidemiol Psichiatr Soc 2006; 15:161-166.
18. Kessler RC, Andrews G, Mroczek D, et al. The World Health Organization Composite International Diagnostic Interview Short Form (CIDI-SF). Int J Methods Psyciatr Res 1998; 7:171-185.
19. Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13:93-121.
20. Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 2005; 58:668-676.
21. Haro JM, Arbabzadeh-Bouchez S, Brugha TS, et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods Psychiatr Res 2006; 15:167-180.
22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV axis I disorders, research version, nonpatient edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
23. Robins LN, Regier DA, editors. Psychiatric Disorders disorders in America: The Epidemiologic Catchment Area Study. New York: The Free Press; 1991.
24. Simon GE, VonKorff M. Recall of psychiatric history in cross-sectional surveys: implications for epidemiologic research. Epidemiol Rev 1995; 17:221-227.
25. Knauper B, Cannell CF, Schwarz N, et al. Improving the accuracy of major depression age of onset reports in the US National Comorbidity Survey. Int J Methods Psyciatr Res 1999; 8:39-48.
26. de Girolamo G, Polidori G, Morosini PL, et al. Prevalence of common mental disorders in Italy. Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD). Soc Psychiatry Psychiatr Epidemiol 2006; 41:853-861.
27. Lee S, Tsang A, Zhang MY, et al. Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol Med 2007; 37:61-71.
28. Medina-Mora M-E, Borges G, Lara C, et al. Prevalence, age of onset, and demographic correlates of DSM-IV psychiatric disorders in Mexico: Results from the Mexican Psychiatric Survey. Psychol Med (in press).
29. Oakley Browne MA, Wells JE, Scott KM, McGee MA. Lifetime prevalence and projected lifetime risk of DSM-IV disorders in Te Rau Hinengaro: the New Zealand Mental Health Survey. Aust N Z J Psychiatry 2006; 40:865-874.
30. Gureje O, Lasebikan VO, Kola L, Makanjuola VA. Lifetime and 12-month prevalence of mental disorders in the Nigerian Survey of Mental Health and Well Being. Br J Psychiatry 2006; 188:465-471.
31. Haro JM, Palacin C, Vilagut G, et al. Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain study. Med Clin (Barc) 2006; 126:445-451.
32. Bromet EJ, Gluzman SF, Paniotto VI, et al. Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey. Soc Psychiatry Psychiatr Epidemiol 2005; 40:681-690.
33. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593-602.
34. The WHO World Mental Health Survey Consortium. Lifetime prevalence and age-of-onset distributions of mental disorders in the WHO World Mental Health (WMH) Surveys. Bull World Health Organ (in press).
35. Thomsen PH. Schizophrenia with childhood and adolescent onset - a nationwide register-based study. Acta Psychiatr Scand 1996; 94:187-193.
36. Jacobi F, Wittchen HU, Holting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004; 34:597-611.
37. Kessler RC. The prevalence of psychiatric comorbidity. In: Wetzler S, Sanderson WC, editors. Treatment strategies for patients with psychiatric comorbidity. New York, NY: John Wiley & Sons; 1997. pp. 23-48.
38. Krueger RF, Chentsova-Dutton YE, Markon KE, et al. A cross-cultural study of the structure of comorbidity among common psychopathological syndromes in the general healthcare setting. J Abnorm Psychol 2003; 112:437-447.
39. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39:964-971.
40. Thompson KN, Conus PO, Ward JL, et al. The initial prodrome to bipolar affective disorder: prospective case studies. J Affect Disord 2003; 77:79-85.
41. McGue M, Iacono WG. The association of early adolescent problem behavior with adult psychopathology. Am J Psychiatry 2005; 162:1118-1124.
42. Rosenbaum JF, Biederman J, Hirshfeld-Becker DR, et al. A controlled study of behavioral inhibition in children of parents with panic disorder and depression. Am J Psychiatry 2000; 157:2002-2010.
43. Christie KA, Burke JDJ, Regier DA, et al. Epidemiologic evidence for early onset of mental disorders and higher risk of drug-abuse in young-adults. Am J Psychiatry 1988; 145:971-975.
44. WHO International Consortium in Psychiatric Epidemiology. Cross-national comparisons of the prevalences and correlates of mental disorders. Bull World Health Organ 2000; 78:413-426.
45. Loeber R, Burke JD, Lahey BB, et al. Oppositional defiant and conduct disorder: a review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry 2000; 39:1468-1484.
46. Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 2000; 9:541-555; vii.
47. Murray CJL, Lopez AD. Global Health Statistics. Cambridge: Harvard University Press; 1996.
48. Christiana JM, Gilman SE, Guardino M, et al. Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders: an international survey of members of mental health patient advocate groups. Psychol Med 2000; 30:693-703.
49. Murrin LC, Sanders JD, Bylund DB. Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: Implications for differential drug effects on juveniles and adults. Biochem Pharmacol 2007; 73:1225-1236.
50. White HR, Morgan TJ, Pugh LA, et al. Evaluating two brief substance-use interventions for mandated college students. J Stud Alcohol 2006; 67:309-317.